METHODS OF MANUFACTURING A BIFUNCTIONAL COMPOUND, ULTRAPURE FORMS OF THE BIFUNCTIONAL COMPOUND, AND DOSAGE FORMS COMPRISING THE SAME

The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide,...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	ALLAN, LAURA E.N, REECE, HAYLEY, GROSSO, JOHN A, REO, JOSEPH P, HASKELL, III, KAUSHAL, ADITYA MOHAN, NEESER, MIRANDA ANNELL, REEVE, MAXWELL MARCO, KENNEDY, SAMUEL ELLIOTT, KATTUBOINA, VENKATA A, ZAHEDI, MOHAMMAD MEHDI, CHEN, CHUNGPIN HERMAN, ROBERTSON, JEROD, QIU, YUPING, LLOYD, RHYS, DONG, HANQING, JAGER, CASEY KEITH, DUGUID, ROBERT J
Format:	Patent
Sprache:	eng ; fre
Schlagworte:	CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A: The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer. La présente invention concerne des formes ultra-pures, des polymorphes, des formes amorphes et des formulations de N-[(1r,4r)-4-(3-chloro-4-cyanophénoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopipéridin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]pipérazin-1-yl}méthyl)pipéridin-1-yl]pyridazine-3-carboxamide, appelé ici composé A : La présente invention concerne également des procédés de fabrication et de purification de ceux-ci, ainsi que des intermédiaires utiles dans la synthèse du composé A. Les formes ultra-pures, polymorphes, formes amorphes et formulations du composé A peuvent être utilisés en tant qu'agents thérapeutiques pour le traitement de diverses maladies et états tels que le cancer.